Senti Biosciences, Inc. (SNTI)
NASDAQ: SNTI · IEX Real-Time Price · USD
2.440
-0.110 (-4.31%)
At close: Jul 19, 2024, 4:00 PM
2.420
-0.020 (-0.82%)
Pre-market: Jul 22, 2024, 7:39 AM EDT
Senti Biosciences Revenue
Senti Biosciences had revenue of $1.28M in the twelve months ending March 31, 2024. In the year 2023, Senti Biosciences had annual revenue of $2.56M.
Revenue (ttm)
$1.28M
Revenue Growth
-71.47%
P/S Ratio
8.76
Revenue / Employee
$26,563
Employees
48
Market Cap
11.16M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.56M | -1.73M | -40.25% |
Dec 31, 2022 | 4.29M | 1.53M | 55.23% |
Dec 31, 2021 | 2.76M | 2.20M | 387.81% |
Dec 31, 2020 | 566.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSNTI News
- 5 days ago - Senti Bio Announces Reverse Stock Split - GlobeNewsWire
- 21 days ago - Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy - GlobeNewsWire
- 2 months ago - Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia - GlobeNewsWire
- 2 months ago - Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights - GlobeNewsWire
- 2 months ago - Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML) - GlobeNewsWire
- 4 months ago - Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights - GlobeNewsWire
- 7 months ago - Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program - GlobeNewsWire
- 7 months ago - Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia - GlobeNewsWire